These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28364582)

  • 41. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
    Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma.
    Heinze B; Herrmann LJ; Fassnacht M; Ronchi CL; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
    Eur J Endocrinol; 2014 May; 170(5):707-17. PubMed ID: 24566897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.
    Worrillow L; Baskaran P; Care MA; Varghese A; Munir T; Evans PA; O'Connor SJ; Rawstron A; Hazelwood L; Tooze RM; Hillmen P; Newton DJ
    Oncogene; 2016 Oct; 35(40):5328-5336. PubMed ID: 27041575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
    Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
    J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Thomay K; Fedder C; Hofmann W; Kreipe H; Stadler M; Titgemeyer J; Zander I; Schlegelberger B; Göhring G
    Ann Hematol; 2017 Sep; 96(9):1493-1500. PubMed ID: 28691153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
    Tracy I; Tapper W; Parker A; Gardiner A; Sadullah S; Pratt G; Copplestone A; Oscier D; Best OG
    Br J Haematol; 2017 Sep; 178(5):824-826. PubMed ID: 27292869
    [No Abstract]   [Full Text] [Related]  

  • 47. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
    Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
    Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.
    Kantorova B; Malcikova J; Smardova J; Pavlova S; Trbusek M; Tom N; Plevova K; Tichy B; Truong S; Diviskova E; Kotaskova J; Oltova A; Patten N; Brychtova Y; Doubek M; Mayer J; Pospisilova S
    Tumour Biol; 2015 May; 36(5):3371-80. PubMed ID: 25527155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
    Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia.
    Ganster C; Neesen J; Zehetmayer S; Jäger U; Esterbauer H; Mannhalter C; Kluge B; Fonatsch C
    Genes Chromosomes Cancer; 2009 Sep; 48(9):760-7. PubMed ID: 19484764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TP53 Gene Pro72Arg (rs1042522) Single Nucleotide Polymorphism as Not a Risk Factor for Colorectal Cancer in the Iranian Azari Population.
    Asadi M; Shanehbandi D; Zarintan A; Pedram N; Baradaran B; Zafari V; Shirmohamadi M; Hashemzadeh S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3423-3427. PubMed ID: 29286614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
    Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
    PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.
    Mechanic LE; Bowman ED; Welsh JA; Khan MA; Hagiwara N; Enewold L; Shields PG; Burdette L; Chanock S; Harris CC
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):214-22. PubMed ID: 17301252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.
    Wang C; Wang X
    Int J Clin Exp Pathol; 2013; 6(7):1223-9. PubMed ID: 23826404
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
    Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
    J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
    Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
    HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
    Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
    Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia.
    Sun Q; Wang L; Zhu HY; Miao Y; Wu W; Liang JH; Cao L; Xia Y; Wu JZ; Wang Y; Wang R; Fan L; Xu W; Li JY
    Chin Med J (Engl); 2019 Mar; 132(5):525-533. PubMed ID: 30741830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients.
    Yalçın S; Mutlu P; Çetin T; Sarper M; Özgür G; Avcu F
    Turk J Haematol; 2015 Dec; 32(4):311-6. PubMed ID: 26376814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.